Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$120,000.00

Extracellular matrix regulation of chemotherapy induced pain.

EF 2024-25

Résumé
Chemotherapy can cause a painful condition called chemotherapy-induced peripheral neuropathy (CIPN), affecting up to 30% of patients even six months after their treatment ends. A common chemotherapy drug, cisplatin, can accumulate in the dorsal root ganglia (DRG), which are peripheral nervous system structures along the spine that contain the cell bodies of nerve cells responsible for sensing pain. However, the reasons behind this lasting pain are still unclear. My research focuses on understanding how cisplatin damages the supporting structure around these nerve cells, known as the extracellular matrix (ECM). This matrix is a meshwork of molecules and proteins that provides structural support and biochemical cues to nerve cells in the DRG, and it may play a role in pain development. Our preliminary findings suggest that cisplatin leads to the breakdown of the ECM and increases immune cell activity in the DRG. These immune cells, such as macrophages and neutrophils, produce enzymes that degrade the ECM, potentially causing long-lasting pain. My hypothesis is that cisplatin stimulates immune cells to degrade the ECM in the DRG, which leads to long-lasting nerve hypersensitivity and pain. To test this, I will use a range of advanced techniques to investigate how cisplatin changes the ECM in the DRG and identify which immune cells are responsible for its breakdown. By understanding this process, we aim to develop new treatments to prevent or reduce chemotherapy-related pain by protecting the ECM from damage.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518947
Name
Alhamwi Allutas
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Extracellular matrix regulation of chemotherapy induced pain.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Behavioural Pharmacology; Chemotherapy-Induced Peripheral Neuropathy; Dorsal Root Ganglia; Ecm Proteases; Extracellular Matrix; Fluorescent In Situ Hybridization (Rnascope); Immune Cells; Pain-Like Behaviour Testing; Sensory Neurons
Abstract
Chemotherapy can cause a painful condition called chemotherapy-induced peripheral neuropathy (CIPN), affecting up to 30% of patients even six months after their treatment ends. A common chemotherapy drug, cisplatin, can accumulate in the dorsal root ganglia (DRG), which are peripheral nervous system structures along the spine that contain the cell bodies of nerve cells responsible for sensing pain. However, the reasons behind this lasting pain are still unclear. My research focuses on understanding how cisplatin damages the supporting structure around these nerve cells, known as the extracellular matrix (ECM). This matrix is a meshwork of molecules and proteins that provides structural support and biochemical cues to nerve cells in the DRG, and it may play a role in pain development. Our preliminary findings suggest that cisplatin leads to the breakdown of the ECM and increases immune cell activity in the DRG. These immune cells, such as macrophages and neutrophils, produce enzymes that degrade the ECM, potentially causing long-lasting pain. My hypothesis is that cisplatin stimulates immune cells to degrade the ECM in the DRG, which leads to long-lasting nerve hypersensitivity and pain. To test this, I will use a range of advanced techniques to investigate how cisplatin changes the ECM in the DRG and identify which immune cells are responsible for its breakdown. By understanding this process, we aim to develop new treatments to prevent or reduce chemotherapy-related pain by protecting the ECM from damage.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Alhamwi, Allutas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~